CHICAGO – A study to assess the accuracy of using liquid biopsies to determine cancer mutations or biomarkers, and thereby assist in treatment decisions, helped to identify approved therapies for 49 percent of the more than 15,000 patients that participated.

Exthera Medical Corp. has closed a series B financing round, with part of the proceeds slated to go toward scale manufacturing of the company's therapeutic blood filter. The round was led by newcomer Fresenius Medical Care Ventures (FMCV) GmbH, with existing investors also participating.